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(Arterial Revascularization Therapies Study–Part II) Trial
Joost Daemen, MD,* Karl Heinz Kuck, MD,† Carlos Macaya, MD,‡ Victor LeGrand, MD,§
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Kristel Wittebols, MSC,§§ Nathalie Macours, PHD,§§ Hans Peter Stoll, MD,§§
Patrick W. Serruys, MD, PHD,* on behalf of the ARTS-II Investigators
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and Waterloo, Belgium; Toulouse, France; and Torino, Italy
Objectives The purpose of this study was to assess the 3-year outcome of coronary artery bypass graft surgery (CABG) and
percutaneous coronary intervention (PCI) using sirolimus-eluting stents (SES) in patients who had multivessel
coronary artery disease with and without diabetes mellitus.
Background The optimal method of revascularization in diabetic patients remains in dispute.
Methods The ARTS-II (Arterial Revascularization Therapies Study–Part II) trial is a single-arm study (n  607) that in-
cluded 159 diabetic patients treated with SES whose 3-year clinical outcome was compared with that of the his-
torical diabetic and nondiabetic arms of the randomized ARTS-I trial (n  1,205, including 96 diabetic patients
in the CABG arm and 112 in the PCI arm).
Results At 3 years, among nondiabetic patients, the incidence of the primary composite of death, CVA, myocardial in-
farction (MI), and repeat revascularization (major adverse cardiac and cerebrovascular events [MACCE]), was
significantly lower in ARTS-II than in ARTS-I PCI (adjusted odds ratio [OR]: 0.41; 95% confidence interval [CI]:
0.26 to 0.64) and similar to ARTS-I CABG. The ARTS-II patients were at significantly lower risk for death, CVA,
and MI as compared with both the ARTS-I PCI (adjusted OR: 0.55; 95% CI: 0.34 to 0.91) and ARTS-I CABG pa-
tients (adjusted OR: 0.56; 95% CI: 0.35 to 0.92). Among diabetic patients, the incidence of MACCE in ARTS-II
was similar to that of both PCI and CABG in ARTS-I. Conversely, the incidence of death, CVA, and MI was signifi-
cantly lower in ARTS-II than in ARTS-I PCI (adjusted OR: 0.67; 95% CI: 0.27 to 1.65) and was similar to that of
ARTS-I CABG.
Conclusions At 3 years, PCI using SES for patients with multivessel coronary artery disease seems to be safer and more effi-
cacious than PCI using bare-metal stents, irrespective of the diabetic status of the patient. Hence, PCI using SES
appears to be a valuable alternative to CABG for both diabetic and nondiabetic patients. (J Am Coll Cardiol
2008;52:1957–67) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.010t
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Impact of Diabetes on 3-Year Outcome in the ARTS-II Trial December 9, 2008:1957–67(BMS), a benefit that proved to
be most apparent among diabetic
patients (1–6).
However, when drug-eluting
stents (DES) were shown to sig-
nificantly reduce the need for
repeat revascularizations, inter-
ventionalists quickly added DES
treatment arms to the pivotal
randomized PCI versus CABG
trials (7,8). As a result, the 1-year
results of the ARTS-II (Arte-
rial Revascularization Therapies
Study–Part II) trial and the
ERACI-III (Argentine Ran-
domized Trial of Coronary An-
gioplasty With Stenting Versus
Coronary Artery Bypass Surgery
in Patients With Multivessel
Disease) study suggested that
PCI using sirolimus-eluting
stents (SES) was safe and effec-
ive and could be a viable alternative for the treatment of
ultivessel coronary artery disease (7,8). Nevertheless, the
igher susceptibility to repeat adverse cardiac events among
iabetic patients makes extrapolation of these findings to
his high-risk patient population uncertain. Diabetic pa-
ients are known to have an accelerated and more aggressive
orm of atherosclerosis with higher restenosis rates and less
avorable long-term survival than nondiabetic patients
9–12). Furthermore, diabetes mellitus has been a strong
nd consistent predictor of late stent thrombosis in patients
reated with DES. This observation has raised some con-
erns about potential erosion of the initial treatment benefit
ue to the occurrence of stent thrombosis, a finding that only
ecame apparent after multiple years of follow-up (13–15).
The present study reports on the 3-year safety and
ffectiveness of SES for diabetic patients with multivessel
isease in the ARTS-II trial compared with the historical
utcomes of the surgical and percutaneous arms of the
RTS-I study.
ethods
RTS-II study design. The ARTS-II study is a multi-
enter, nonrandomized, open label trial designed to assess
he safety and efficacy of SES for patients with de novo
ultivessel coronary artery disease and compare them with
he surgical group of the ARTS-I trial as a historical control
16). To obtain a population comparable to that of the
RTS-I trial, patients were stratified by clinical site to
nsure the inclusion of at least one-third of patients with
-vessel disease.
Patients were eligible for coronary revascularization if
hey had either stable angina (Canadian Cardiovascular
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft surgery
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
CVA  cerebrovascular
accident
DES  drug-eluting stent(s)
MACCE  major adverse
cardiac and
cerebrovascular event(s)
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)ociety functional class I to IV), unstable angina (Braun- tald class I to IIIB or C), or silent ischemia, and at least 2
esions located in different major epicardial vessels, includ-
ng their side branches (except for the left main coronary
rtery), that were potentially amenable to stent implantation
17,18). Patients were required to have multivessel disease
hat included treatment of the left anterior descending
rtery and at least 1 other significant lesion (50% diameter
tenosis) in another major epicardial coronary artery. The
oal was to achieve complete anatomic revascularization
19). One totally occluded major epicardial vessel or side
ranch could be included. The stenosis had to be amenable
o stenting using an SES with a diameter of 2.5 to 3.5 mm
nd a length of 13 to 33 mm, without restriction on the total
mplanted stent length. Decisions to place stents in lesions
ith bifurcations, fresh thrombus, calcification, diffuse dis-
ase, complex anatomy, or stenting of side branches were
eft to the discretion of the operators.
Patients with previous coronary intervention, left main
oronary artery disease, overt congestive heart failure, or a
eft ventricular ejection fraction of 30% were excluded.
dditional exclusion criteria were as follows: history of
erebrovascular accident (CVA), transmural myocardial in-
arction (MI) in the preceding week, severe hepatic or renal
isease, neutropenia or thrombocytopenia, intolerance of or
ontraindication to acetylsalicylic acid or thienopyridines,
eed for concomitant major surgery, and life-limiting major
oncomitant noncardiac diseases. Written informed consent
as obtained from each patient before enrollment. The
tudy was approved by the ethics committee of each partic-
pating site.
tudy population. Between April 1997 and June 1998, a
otal of 1,205 patients was randomly assigned to PCI with
MS (n  600) or CABG (n  605) at 67 participating
enters in the ARTS-I trial. Diabetes mellitus was present
n 112 patients in the ARTS-I BMS arm and in 96 patients
n the ARTS-I CABG arm. Between February 2003 and
ovember 2003, 607 patients, of whom 159 were diabetic,
ere treated with SES at 45 participating centers in the
RTS-II trial.
tudy objectives. The primary objective of this study was
o assess the safety and efficacy of SES in the ARTS-II
tudy as compared with both the stent and the surgical arms
f the ARTS-I trial among patients with or without
iabetes. The primary safety end point was the composite
nd point of death, MI, and CVA. The primary efficacy end
oint was major adverse cardiac and cerebrovascular events
MACCE), defined as the occurrence of major adverse
ardiac and cerebrovascular accidents, death, stroke, MI,
nd ischemia-driven repeat revascularization. Secondary end
oints were the itemized outcome parameters of death,
VA, MI, repeat revascularization, and stent thrombosis in
he ARTS-II population.
aseline and end point definitions. Hypertension was
efined as blood pressure140 mm Hg systolic or90 mm
g diastolic or was based on current antihypertensivereatment. Dyslipidemia was classified as total serum cho-
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December 9, 2008:1957–67 Impact of Diabetes on 3-Year Outcome in the ARTS-II Trialesterol level 6.2 mmol/l or the use of lipid-lowering
rugs. Death was categorized as cardiac or noncardiac.
erebrovascular events were divided into 3 main categories:
troke, transient ischemic attacks, and reversible ischemic
eurologic deficits. All repeat revascularization procedures
ere recorded. In the first 7 days after the intervention, a
efinite diagnosis of MI was made if there was documen-
ation of new abnormal Q waves and either a ratio of serum
reatine kinase-myocardial band (CK-MB) isoenzyme to
aseline Patient Demographics and Clinical Characteristics in Non
Table 1 Baseline Patient Demographics and Clinical Character
Nondiabetic Patients
ARTS-II
(n  448)
Baseline characteristics
Male, % 80.1
Age, yrs  SD 62.1  9.9
Body mass index, kg/m2  SD 27.1  3.8
Risk factors, %
Hypertension 62.7
Hypercholesterolemia 74.0
Family history of MI or sudden death age 55 yrs 36.7
Current smoker 21.9
Peripheral vascular disease 6.5
Previous MI 36.2
Indication for treatment, %
Stable angina 53.1
Unstable angina 37.9
Silent ischemia 8.9
Angiographic characteristics
Ejection fraction, % 60  12
No. of lesions with stenosis 50%, n  SD 3.6  1.3
No. of diseased vessels, %
1 0.2
2 45.1
3 54.7
Vessel territory with stenosis, % of lesions
Right coronary artery 29.3
Left main coronary artery 0.0
Left anterior descending artery 41.8
Left circumflex artery 28.9
Lesion length, visual (mm), % of lesions
Discrete, 10 63.2
Tubular, 10–20 26.0
Diffuse, 20 10.8
Lesion classification, % of lesions
Type A 6.9
Type B1 24.4
Type B2 55.7
Type C 12.9
Procedural characteristics
Bifurcation requiring double wiring, % 34.7
Number of stents implanted  SD 3.7  1.5
Total stent length, mm  SD 72.0  32.1
Maximum dilatation pressure, atm  SD 16.4  2.9
Direct stenting, % of lesions 36.0
GP IIb/IIIa inhibitors during procedure, % 31.9
Duration of procedure, min  SD 86  44
Post-procedural hospital stay, days  SD 3.3  2.6RTS  Arterial Revascularization Therapies Study; CABG  coronary artery bypass graft surgery; GP otal cardiac enzyme that was 0.1 or a CK-MB value that
as 5 times the upper limit of normal (20). Serum creatine
inase and CK-MB isoenzyme concentrations were mea-
ured 6, 12, and 18 h after the intervention. Beginning 8
ays after the intervention (the length of the hospital stay
fter surgery), either abnormal Q waves or enzymatic changes,
s described in the previous text, were sufficient for a diagnosis
f MI. An MI was confirmed only after the relevant electro-
ardiograms had been analyzed by the core laboratory and
tic Patients
in Nondiabetic Patients
-I–CABG
 488)
ARTS-I–PCI
(n  509)
ARTS-II:I–CABG
p Value
ARTS-II:I–PCI
p Value
77.4 77.9 0.34 0.42
 9.4 60.2  9.7 0.07 0.004
 3.6 26.9  3.6 0.54 0.38
42.8 40.2 0.001 0.001
59.3 58.6 0.001 0.001
43.7 38.6 0.029 0.54
27.5 29.6 0.051 0.007
4.7 5.5 0.26 0.58
40.7 41.1 0.16 0.006
57.2 55.7 0.22 0.43
37.9 37.7 1.00 0.95
4.9 6.6 0.015 0.18
 13 61  12 0.94 0.45
 1.0 2.8  0.9 0.001 0.001
4.2 4.0 0.001 0.001
66.7 69.3 0.001 0.001
29.0 26.7 0.001 0.001
29.6 31.3 0.87 0.24
0.1 0.1 0.46 0.45
41.2 40.1 0.74 0.36
29.2 28.5 0.90 0.84
67.4 67.0 0.023 0.041
26.0 25.8 0.97 0.97
6.6 7.2 0.001 0.001
6.8 6.5 0.88 0.65
31.8 26.4 0.001 0.23
53.5 58.9 0.23 0.10
7.9 8.2 0.001 0.001
30.8 35.0 0.029 0.90
— 2.7  1.2 — 0.001
— 46.4  20.6 — 0.001
— 14.6  2.8 — 0.001
— 3.4 — 0.001
— 0.0 — —
 67 98  50 0.001 0.001
 4.3 3.8  3.7 0.001 0.031diabe
istics
ARTS
(n
61.0
27.2
60
2.7
191
9.4glycoprotein; MI  myocardial infarction; PCI  percutaneous coronary intervention.
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Impact of Diabetes on 3-Year Outcome in the ARTS-II Trial December 9, 2008:1957–67djudicated by the clinical events committee. This 2-part
ethod of defining MI was developed for the ARTS-I study
o address the difficulty of diagnosing MI after surgery (16).
hese definitions have been adopted by the Academic Re-
earch Consortium (ARC) and are applied whenever a com-
arison is made between DES and surgery (21).
-year clinical follow-up. The study protocol required all
atients to have clinical follow-up including registration of
n electrocardiogram at 1 month, 6 months, 1 year, and 3
ears. At each visit, physical examination, anginal status,
nd use of medications were assessed. Additional informa-
ion was obtained by telephone interview or from the
eferring physician when needed. An independent commit-
ee adjudicated clinical events and electrocardiograms.
uality of life was assessed (by the European Quality of Life
ndex and 36-Item Short-Form Health Survey) at 1 month,
months, 1 year, and 3 years. Finally, complete 3-year
ollow-up was available for 99% of the patients in all
reatment arms.
nd point measurement. In the ARTS-II study, the
rocedure was performed within 48 h after inclusion. In the
RTS-I trial, patients were randomly allocated to treatment
fter informed consent had been obtained and then entered
n a waiting list. Three deaths occurred in the ARTS-I
ABG arm while these patients were still on the waiting list
or surgery. To compensate for the temporal difference since
llocation between groups, events for the present report
ere counted from time of procedure for all 3 arms and not
rom time of allocation, as previously published (3,22,23).
In both the ARTS-I and -II studies, only data on
ubacute thrombotic occlusions (30 days) were collected
n the case record form. In ARTS-II, stent thrombosis was
linical End Points at 3 Years in Nondiabetic Patients (Hierarchicao hierarchical MACCE to 1,080 Days, p r Patient) Counted Since
Table 2 Clinical End Points at 3 Years in Nondiabetic PatientsNonhierarchical MACCE to 1,080 Days, per Patient) C
Up to 1,080 Days
ARTS-II
(n  448)
ARTS-I–CABG
(n  506)
MACCE* 16.3% (73) 15.8% (80)
Death/CVA/MI* 7.8% (35) 10.3% (52)
Death/MI* 6.0% (27) 8.5% (43)
Death 2.2% (10) 4.2% (21)
Cardiac death 1.1% (5) 2.4% (12)
Noncardiac death 1.1% (5) 1.8% (9)
CVA 2.5% (11) 2.6% (13)
Myocardial infarction 4.0% (18) 4.9% (25)
Q-wave 2.5% (11) 4.5% (23)
Non–Q-wave 1.8% (8) 0.4% (2)
Revascularization 11.8% (53) 6.3% (32)
CABG 1.8% (8) 1.0% (5)
CABG TL 0.4% (2) 0.8% (4)
CABG non-TL 1.3% (6) 0.2% (1)
RPTCA 10.3% (46) 5.9% (30)
RPTCA TL 5.8% (26) 3.8% (19)
RPTCA non-TL 5.8% (26) 2.4% (12)
alues are % (n) unless otherwise indicated. *Hierarchical. MACCE was defined as death, CVA, MI, ta
vents committee.CI confidence interval; CVA cerebrovascular accident; MACCEmajor adverse cardiac and cereb
isk; TL  target lesion; other abbreviations as in Table 1.eadjudicated according to the ARC definitions (21). In this
rocess, all coronary angiograms in the ARTS-II study,
oth procedure related (n  104) and nonprocedure-related
n 165), were reviewed by an independent core laboratory
nd adjudicated by an independent critical events commit-
ee. Thus far, no attempt has been made to assess data on
tent thrombosis in the ARTS-I study in a similar fashion.
tatistical analysis. Demographic and procedural charac-
eristics of diabetic patients were compared between
RTS-II and -I (CABG and PCI). A similar comparison
as performed for nondiabetic patients, and for diabetic
atients versus nondiabetic patients in the ARTS-II trial.
ontinuous variables are expressed as mean  SD. Binary
ariables are reported as percentages, and the difference
etween groups is presented with 95% confidence intervals
CIs). The 2-group t test for continuous variables and the
isher exact test for categorical variables were used. Item-
zed MACCE rates at 3 years are presented as counts and
ercentages and were compared in terms of relative risks
ARTS-II vs. both ARTS-I arms) with 95% CI. Time-to-
vent variables are presented as Kaplan-Meier curves, and
he overall incidence was tested using the log-rank test.
A separate multivariate regression analysis was performed
o further study treatment effects, considering potential
onfounders listed in Table 1. Baseline and procedural
haracteristics listed in Table 1 were tested on a per-patient
asis by univariate analysis to determine suitability for
nclusion in the multivariate model. Finally, a logistic
egression model was built using the statistically significant
nivariate predictors (p  0.1). The Hosmer and Leme-
how test was used to assess the goodness of fit of the
ultivariable models.
e of Procedure
archical and
d Since Date of Procedure
ARTS-I–PCI
(n  488)
ARTS-II:I–CABG
RR (95% CI)
ARTS-II:I–PCI
RR (95% CI)
30.9% (151) 1.03 (0.77–1.38) 0.53 (0.41–0.67)
11.5% (56) 0.76 (0.50–1.14) 0.68 (0.46–1.02)
9.0% (44) 0.71 (0.45–1.13) 0.67 (0.42–1.06)
3.3% (16) 0.54 (0.26–1.13) 0.68 (0.31–1.48)
1.8% (9) 0.47 (0.17–1.33) 0.61 (0.20–1.79)
1.4% (7) 0.63 (0.21–1.86) 0.78 (0.25–2.43)
2.9% (14) 0.96 (0.43–2.11) 0.86 (0.39–1.87)
6.1% (30) 0.81 (0.45–1.47) 0.65 (0.37–1.16)
5.3% (26) 0.54 (0.27–1.10) 0.46 (0.23–0.92)
1.0% (5) 4.52 (0.96–21.16) 1.74 (0.57–5.29)
23.6% (115) 1.87 (1.23–2.85) 0.50 (0.37–0.68)
8.2% (40) 1.81 (0.60–5.48) 0.22 (0.10–0.46)
6.1% (30) 0.56 (0.10–3.07) 0.07 (0.02–0.30)
2.0% (10) 6.78 (0.82–56.07) 0.65 (0.24–1.78)
17.8% (87) 1.73 (1.11–2.69) 0.58 (0.41–0.80)
13.1% (64) 1.55 (0.87–2.75) 0.44 (0.29–0.69)
6.4% (31) 2.45 (1.25–4.79) 0.91 (0.55–1.51)
sel CABG, and target vessel RPTCA; death, CVA, andMI are adjudicated by the independent clinicall andDat
(Hier
ounte
rget vesrovascular events; RPTCA repeat percutaneous transluminal coronary angioplasty; RR relative
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ondiabetic patients in the ARTS-I and -II trials. BASE-
INE CHARACTERISTICS. Baseline and procedural charac-
eristics of the nondiabetic patients from ARTS-II and -I
re depicted in Table 1. In brief, the ARTS-II patients had
ypertension and hypercholesterolemia significantly more
ften than did both the ARTS-I CABG and PCI cohorts.
atients from the ARTS-II trial presented significantly
ore often with 3-vessel disease and type C lesions as
ompared with both ARTS-I PCI and CABG patients.
inally, as compared with ARTS-I PCI patients, ARTS-II
atients received significantly more stents, which resulted in
significantly longer total stented length.
Clinical end points at 3 years are depicted in Table 2. In
rief, the MACCE rate among the ARTS-II nondiabetic
atients was significantly lower than that in the ARTS-I
CI arm and similar to that in the ARTS-I CABG arm
Fig. 1A). Adjustment for independent predictors of the
ombined end point of MACCE resulted in an odds ratio
OR) of 0.41 (95% CI: 0.26 to 0.64) for ARTS-II versus -I
CI and an OR of 0.83 (95% CI: 0.56 to 1.23) for ARTS-II
ersus -I CABG. There was a trend toward a lower
ncidence of the combined safety end point of death/
VA/MI among nondiabetic patients from the ARTS-II
rial as compared with both arms of the ARTS-I trial; and
t reached statistical significance after adjustment for inde-
endent predictors for ARTS-II versus -I CABG (OR:
.56; 95% CI: 0.35 to 0.92) and for ARTS-II versus -I PCI
OR: 0.55; 95% CI: 0.34 to 0.91) (Fig. 1B). The need for
epeat revascularizations remained significantly higher in
RTS-II than in ARTS-I CABG, but was significantly
ower than in ARTS-I PCI. Adjustment for independent
redictors of the combined end point of revascularization
esulted in an OR of 1.36 (95% CI: 0.80 to 2.29) for
RTS-II versus -I CABG and an OR of 0.43 (95% CI:
.27 to 0.69) for ARTS-II versus -I PCI.
iabetic patients in the ARTS-I and -II trials. BASELINE
HARACTERISTICS. Baseline clinical and procedural char-
cteristics of the diabetic patients are presented in Table 3.
imilar to the nondiabetic population, the ARTS-II dia-
etic patients had a significantly higher rate of hypertension
nd hypercholesterolemia as compared with both the
RTS-I CABG and PCI cohorts. Patients from the
RTS-II trial presented significantly more often with
-vessel disease and type C lesions compared with both the
RTS-I PCI and CABG patients. Finally, as compared
ith ARTS-I PCI, ARTS-II patients received significantly
ore stents, which resulted in a significantly longer total
tented length.
The 3-year results of the ARTS-II diabetic patients,
ompared with both arms of the randomized ARTS-I trial,
re depicted in Table 4. In brief, the MACCE rate in
RTS-II was significantly lower than that in the ARTS-I
CI arm and was similar to that in the ARTS-I CABG armFig. 2A). Adjustment for independent predictors of dACCE resulted in an OR of 0.72 (95% CI: 0.37 to 1.37)
or ARTS-II versus -I PCI and an OR of 1.08 (95% CI:
.41 to 2.84) for ARTS-II versus -I CABG. The incidence
f death/CVA/MI was significantly lower among the
RTS-II patients than among the ARTS-I PCI cohort, but
as similar to that of the ARTS-I CABG arm (Fig. 2B).
djustment for independent predictors of the combined end
oint of death/CVA/MI resulted in an OR of 0.67 (95%
I: 0.27 to 1.65) for ARTS-II versus -I PCI and an OR of
.67 (95% CI: 0.29 to 1.57) for ARTS-II versus -I CABG.
As expected, the MACCE rate was higher among dia-
etic patients receiving insulin therapy than among patients
ot receiving insulin treatment (Fig. 3). The 23.6% differ-
nce in MACCE rates between the insulin-treated and
oninsulin-treated diabetic patients in the CABG arm is
orth noting. However, there were only 16 insulin-treated
Figure 1 Kaplan-Meier Curve to 3 Years
for ARTS-I and -II Nondiabetic Patients
(A) Freedom from major adverse cardiac and cerebrovascular events, the com-
bined end point of all-cause death, cerebrovascular accident (CVA), myocardial
infarction (MI), and repeat revascularization, and (B) death/CVA/MI. ARTS 
Arterial Revascularization Therapies Study; CABG  coronary artery bypass
graft surgery; CI  confidence interval; PCI  percutaneous coronary interven-
tion; RR  relative risk.iabetic patients in the ARTS-II CABG arm, a number
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he relative treatment effect among insulin-treated diabetic
atients.
he impact of diabetes in the ARTS-II trial. After
djustment for independent predictors, diabetes proved to
aseline Patient Demographics and Clinical Characteristics in Diab
Table 3 Baseline Patient Demographics and Clinical Character
Diabetic Patients
ARTS-II
(n  159)
Baseline characteristics
Male, % 66.7
Age, yrs  SD 64.5  8.7
Body mass index, kg/m2  SD 28.9  4.6
Risk factors, %
Diabetes, insulin treated 17.6
Hypertension 79.9
Hypercholesterolemia 74.1
Family history of MI or sudden death age 55 yrs 33.8
Current smoker 11.9
Peripheral vascular disease 8.2
Previous MI 29.6
Indication for treatment, %
Stable angina 53.5
Unstable angina 32.1
Silent ischemia 14.5
Angiographic characteristics
Ejection fraction, % 60  12
No. of lesions with stenosis 50%, n  SD 3.6  1.3
No. of diseased vessels, %
1 0.6
2 49.1
3 50.3
Vessel territory with stenosis, % of lesions
Right coronary artery 28.5
Left main coronary artery 0.0
Left anterior descending artery 40.7
Left circumflex artery 30.8
Lesion length, visual, mm (% of lesions)
Discrete, 10 54.4
Tubular, 10–20 30.9
Diffuse, 20 14.7
Lesion classification, % of lesions
Type A 6.6
Type B1 20.4
Type B2 56.4
Type C 16.7
Procedural characteristics
Bifurcation requiring double wiring, % 31.9
Number of stents implanted  SD 3.6  1.5
Total stent length, mm  SD 73.9  31.9
Maximum dilatation pressure, atm  SD 16.2  2.7
Direct stenting, % of lesions 30.6
GP IIb/IIIa inhibitors during procedure, % 34.0
Duration of procedure, min  SD 83  40
Post-procedural hospital stay, days  SD 3.6  2.9
umbers are % (counts/available field sample size) or mean  1 SD.
Abbreviations as in Tables 1 and 2.e the strongest pre-procedural predictor of MACCE in the pRTS-II trial (OR: 1.76; 95% CI: 1.13 to 2.74, p  0.012)
24). The clinical end points of the ARTS-II diabetic
atients versus nondiabetic patients are depicted in Table 5.
n brief, the incidence of MACCE among diabetic patients
as significantly higher than it was among nondiabetic
Patients
in Diabetic Patients
-I–CABG
 96)
ARTS-I–PCI
(n  112)
ARTS-II:I–CABG
p Value
ARTS-II:I–PCI
p Value
68.8 73.2 0.78 0.29
 9.2 62.5  9.1 0.09 0.08
 3.8 28.7  3.7 0.16 0.78
16.7 20.5 1.0 0.64
56.3 64.3 0.001 0.005
49.0 55.4 0.001 0.002
32.6 41.4 0.89 0.20
16.7 20.5 0.35 0.06
7.3 5.4 1.00 0.47
49.0 41.4 0.002 0.053
62.5 58.9 0.19 0.39
33.3 37.5 0.89 0.37
4.2 3.6 0.011 0.003
 14 61  13 0.64 0.54
 1.1 2.9  1.2 0.001 0.001
1.0 3.7 1.00 0.16
63.5 65.4 0.028 0.012
35.4 30.8 0.027 0.002
29.0 30.4 0.94 0.59
0.0 0.0 — —
40.7 36.6 1.00 0.25
30.3 33.0 0.94 0.54
71.9 59.9 0.001 0.13
21.7 33.8 0.005 0.40
6.4 6.4 0.001 0.001
7.2 3.6 0.77 0.06
29.0 26.2 0.006 0.051
56.2 62.8 1.00 0.07
7.6 7.4 0.001 0.001
36.3 32.6 0.21 0.88
— 3.0  1.5 — 0.002
— 52.7  25.6 — 0.001
— 14.9  2.9 — 0.001
— 2.6 — 0.001
— 0.0 — —
 64 104  51 0.001 0.001
 7.3 4.6  3.4 0.001 0.012etic
istics
ARTS
(n
62.6
28.1
60
3.0
201
11.0atients. This difference was mainly driven by the signif-
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December 9, 2008:1957–67 Impact of Diabetes on 3-Year Outcome in the ARTS-II Trialcantly higher need for repeat revascularizations among
he diabetic patients. At 3 years, the difference between
iabetic and nondiabetic patients in the incidence of the
ombined safety end point of death/CVA/MI did not
each statistical significance.
Remarkably, the incidence of stent thrombosis (definite,
robable, or possible) at 3 years was similar for the ARTS-II
iabetic and nondiabetic patients (6.9% [11 of 159] vs. 6.3%
28 of 448], respectively; p  0.85). Definite or probable
tent thrombosis occurred in 5.0% (8 of 159) of the diabetic
atients as compared with 5.4% (24 of 448) of the nondi-
betic patients (p  1.00), whereas the incidence of only
efinite stent thrombosis was 3.8% (6 of 159) for the
iabetic patients and 3.3% (15 of 448) for nondiabetic
atients (p  0.8). There were no differences in the
ncidence of stent thrombosis between insulin- and
oninsulin-treated diabetic patients. Definite or probable
tent thrombosis occurred in 4.6% (6 of 131) of the
oninsulin-treated diabetic patients versus 7.1% (2 of 28) of
he insulin-treated diabetic patients (p  0.63).
Among the diabetic patients, of the 44 patients who had
major adverse cardiac event (ARC definitions), 10 (22.7%)
ad a definite, probable, or possible stent thrombosis. Of
he 83 nondiabetic patients in the ARTS-II study who had
major adverse cardiac event, 28 (33.7%) had a definite,
robable, or possible stent thrombosis. More specifically, 5
f 26 (19.2%) of the clinically driven percutaneous target
esion revascularizations in the nondiabetic patients and 12
f 22 (54.5%) of the clinically driven percutaneous target
esion revascularizations in the diabetic patients were due to
linical End Points at 3 Years in Diabetic Patients (Hierarchicalnd Nonhierarchical MACCE to 1,080 Days, per Patient) Counted S
Table 4 Clinical End Points at 3 Years in Diabetic Patients (Hieand Nonhierarchical MACCE to 1,080 Days, per Patien
Up to 1,080 Days
ARTS-II
(n  159)
ARTS-I–CABG
(n  96)
MACCE* 27.7% (44) 17.7% (17)
Death/CVA/MI* 9.4% (15) 13.5% (13)
Death/MI* 6.9% (11) 9.4% (9)
Death 5.0% (8) 5.2% (5)
Cardiac death 2.5% (4) 4.2% (4)
Noncardiac death 2.5% (4) 1.0% (1)
CVA 3.8% (6) 6.3% (6)
Myocardial infarction 2.5% (4) 5.2% (5)
Q-wave 1.3% (2) 4.2% (4)
Non–Q-wave 1.3% (2) 1.0% (1)
Revascularization 21.4% (34) 7.3% (7)
CABG 3.8% (6) 2.1% (2)
CABG TL 1.3% (2) 1.0% (1)
CABG non-TL 2.5% (4) 1.0% (1)
RPTCA 18.2% (29) 6.3% (6)
RPTCA TL 13.8% (22) 3.1% (3)
RPTCA non-TL 6.9% (11) 3.1% (3)
alues are % (n) unless otherwise indicated. *Hierarchical. MACCE was defined as death, CVA, MI, ta
vents committee.
Abbreviations as in Tables 1 and 2.efinite stent thrombosis. discussion
he present study is the first to compare the long-term
afety and efficacy of PCI using SES with CABG in
iabetic and nondiabetic patients with multivessel coronary
rtery disease. In the total ARTS-II population, we recently
eported the significantly lower incidence of death/
VA/MI among patients treated with SES as compared
ith patients in the historical PCI arm of the ARTS-I
tudy. Stratification of these results according to diabetic
tatus revealed that, when adjusting for independent pre-
ictors of outcome, the risk of death/CVA/MI for the
ondiabetic patients was significantly lower in the ARTS-II
rial than it was in both arms of the ARTS-I study.
onversely, for the diabetic cohort, the cumulative inci-
ence of death/CVA/MI in the ARTS-II trial was 9.2%
ower than it was in the ARTS-I PCI arm and 4.1% lower
han in the ARTS-I CABG arm. However, these differ-
nces in the hard clinical end points did not reach statistical
ignificance after adjusting for independent predictors of
utcome.
Thus far, no consensus has been reached about differences
etween PCI and CABG in hard clinical end points. In the
re-stent era, higher survival rates were reported after
ABG than after PCI, a difference that was most pro-
ounced among diabetic patients (12,25,26). Comparing
CI using BMS with CABG, a meta-analysis of the
RTS-I, the SoS (Stent or Surgery), the ERACI-II, and
he MASS-II (Medicine, Angioplasty, or Surgery Study)
rials demonstrated similar mortality rates after both treat-
ent options in both the overall analysis as well as in the
Date of Procedure
hical
unted Since Date of Procedure
ARTS-I–PCI
(n  112)
ARTS-II:I–CABG
RR (95% CI)
ARTS-II:I–PCI
RR (95% CI)
47.3% (53) 1.56 (0.95–2.57) 0.58 (0.43–0.80)
18.8% (21) 0.70 (0.35–1.40) 0.50 (0.27–0.93)
14.3% (16) 0.74 (0.32–1.72) 0.48 (0.23–1.00)
7.1% (8) 0.97 (0.33–2.87) 0.70 (0.27–1.82)
6.3% (7) 0.60 (0.15–2.36) 0.40 (0.12–1.34)
0.9% (1) 2.42 (0.27–21.29) 2.82 (0.32–24.87)
5.4% (6) 0.60 (0.20–1.82) 0.70 (0.23–2.13)
9.8% (11) 0.48 (0.13–1.75) 0.26 (0.08–0.78)
8.0% (9) 0.30 (0.06–1.62) 0.16 (0.03–0.71)
1.8% (2) 1.21 (0.11–13.14) 0.70 (0.10–4.93)
38.4% (43) 2.93 (1.35–6.35) 0.56 (0.38–0.81)
13.4% (15) 1.81 (0.37–8.79) 0.28 (0.11–0.70)
8.9% (10) 1.21 (0.11–13.14) 0.14 (0.03–0.63)
4.5% (5) 2.42 (0.27–21.29) 0.56 (0.15–2.05)
27.7% (31) 2.92 (1.26–6.77) 0.66 (0.42–1.03)
19.6% (22) 4.43 (1.36–14.40) 0.70 (0.41–1.21)
9.8% (11) 2.21 (0.63–7.74) 0.70 (0.32–1.57)
sel CABG, and target vessel RPTCA; death, CVA, andMI are adjudicated by the independent clinicalince
rarc
t) Co
rget vesiabetic subset at 1 year (2). We observed a clear trend
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Impact of Diabetes on 3-Year Outcome in the ARTS-II Trial December 9, 2008:1957–67oward a lower incidence of death/CVA/MI among the
atients in the ARTS-II trial treated with DES compared
ith the ARTS-I PCI population. Although the present
tudy was underpowered to make definitive statements
bout a better survival after PCI using DES as compared
ith BMS, these findings are in agreement with the 3-year
esults of the randomized DIABETES trial, in which 6.4%
f the patients treated with SES experienced an MI and/or
ied of a cardiac cause versus 12.6% of the patients treated
ith BMS (27). Furthermore, various large-scale registries
ave recently shown a small, but consistent long-term
urvival advantage when using DES versus BMS in all-
omer populations (28–32).
CABG has been associated with a significantly lower risk
or repeat revascularizations as compared with PCI with
MS, a benefit that proved to be most apparent among
atients with multivessel disease, who often have diabetes
Figure 2 Kaplan-Meier Curve to 3 Years
for ARTS-I and -II Diabetic Patients
(A) Freedom from major adverse cardiac and cerebrovascular events (MACCE),
the combined end point of all-cause death, CVA, MI, and repeat revasculariza-
tion, and (B) death/CVA/MI. Abbreviations as in Figure 1.1–6). Although DES proved to tighten the gap between BCI and CABG, it remains unclear whether these findings
an be extrapolated to diabetic patients (7,8). Diabetic
atients are known to have smaller vessel size, longer lesion
ength, greater plaque burden, and possibly a different
estenotic cascade as compared with nondiabetic patients,
aking them more susceptible to atherosclerosis and having
higher need for repeat revascularizations (9–12,33,34).
his observation is confirmed by the 3-year revasculariza-
ion rate among the ARTS-II diabetic patients, who had an
1% increased risk for repeat revascularization as compared
ith that for the nondiabetic patients. The use of CABG
emains the most effective method for avoiding reinterven-
ions in diabetic patients. When compared with the
RTS-I PCI population, the incidence of repeat revascu-
arization was 31% lower after surgical revascularization.
lthough CABG remained significantly superior to PCI
ith DES in reducing the need for repeat revasculariza-
ions, the use of SES in diabetic patients resulted in a
4% decrease in the need for repeat revascularizations as
ompared with the ARTS-I PCI arm, despite the higher
aseline and procedural risk profile of the ARTS-II
atient population. Among the nondiabetic patients,
onversely, these differences were substantially smaller.
he difference was 17.0% between both arms of the
RTS-I trial, whereas the difference in repeat revascu-
arization rates between ARTS-II and -I CABG was
.5%, confirming the more pronounced efficacy of CABG
n diabetic patients.
Diabetes has been associated with enhanced platelet
eactivity and reduced responsiveness to antiplatelet agents
35,36). Abnormalities in neovascularization have also been
ecognized and are hypothesized to enhance atherosclerotic
laque destabilization (37). The latter is reflected by the
0% higher relative risk of MACCE for diabetic patients as
ompared with nondiabetic patients in the ARTS-II trial.
dditionally, the incidence of definite stent thrombosis was
.8% for the diabetic patients, an incidence in line with
hose of previously reported studies (15,27,38). Of note, at
years, the incidence of definite or probable stent throm-
osis (21) was similar among the ARTS-II diabetic and
ondiabetic patients, a finding that at first is not entirely
onsistent with the current literature (13–15) but may be
artly explained by the relatively small and specific patient
opulation studied. Clinical and procedural risk factors are
sually worse for diabetic patients than for nondiabetic
atients. However, in the ARTS-II trial, clinical presenta-
ion, lesion calcification, number of stents, and total stented
ength were similar between the diabetic and nondiabetic
atients. As a result, the impact of stent thrombosis on the
-year MACCE rates in the ARTS-II trial was similar for
oth the diabetic and nondiabetic populations.
Although the present subset analysis of patients with
iabetes was pre-specified in the ARTS-II protocol, this
onrandomized study has several limitations. First, a 5-year
ime lag exists between the groups that are being compared.
oth PCI and CABG as well as concomitant medical
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December 9, 2008:1957–67 Impact of Diabetes on 3-Year Outcome in the ARTS-II Trialherapy have improved with time. Secondly, despite the use
f complex statistical adjustment methods, it remains un-
lear whether we were able to fully adjust for the differences
etween the ARTS-II and -I studies. Third, although the
rotocol required that the lesions in the ARTS-II trial be
otentially treatable by CABG, the absence of dialogue with
he surgeons before the intervention may have caused a
Figure 3 Kaplan-Meier Curve to 3 Years for ARTS-I and -II IDDM
Freedom from major adverse cardiac and cerebrovascular events (MACCE), the com
revascularization. IDDM  insulin-dependent diabetes mellitus; NIDDM  noninsu
linical End Points of Diabetic Patients and Nondiabetic Patients at 3Hierarchical a d Nonhierarchical MACCE to 1,080 Days, per P ie
Table 5 Clinical End Points of Diabetic Patients and Nondiabetic(Hierarchical and Nonhierarchical MACCE to 1,080 Da
Up to 1,080 Days Diabetic Patients (n  159)
MACCE* 27.7% (44)
Death/CVA/MI* 9.4% (15)
Death/MI* 6.9% (11)
Death 5.0% (8)
Cardiac death 2.5% (4)
Noncardiac death 2.5% (4)
CVA 3.8% (6)
Myocardial infarction 2.5% (4)
Q-wave 1.3% (2)
Non–Q-wave 1.3% (2)
Revascularization 21.4% (34)
CABG 3.8% (6)
CABG TL 1.3% (2)
CABG non-TL 2.5% (4)
RPTCA 18.2% (29)
RPTCA TL 13.8% (22)
RPTCA non-TL 6.9% (11)
alues are % (n) unless otherwise indicated. *Hierarchical. MACCE was defined as death, CVA, MI, ta
vents committee.
Abbreviations as in Tables 1 and 2.election bias. However, this bias is not obvious considering
hat the patients actually enrolled in the ARTS-II trial were
ore complex than those enrolled in the ARTS-I trial.
inally, the incidence and impact of stent thrombosis was
ot readjudicated according to the ARC definitions in the
RTS-I study, preventing the authors from comparing the
esults of the ARTS-II trial to the historical PCI arm of the
sus NIDDM Patients
end point of all-cause death, CVA, MI, and repeat
endent diabetes mellitus; other abbreviations as in Figure 1.
s in the ARTS-II Trialou ted Since Date of Procedure
nts at 3 Years in the ARTS-II Trial
er Patient) Counted Since Date of Procedure
Nondiabetic Patients (n  448) Relative Risk (95% CI)
16.3% (73) 1.70 (1.22–2.36)
7.8% (35) 1.21 (0.68–2.15)
6.0% (27) 1.15 (0.58–2.26)
2.2% (10) 2.25 (0.91–5.61)
1.1% (5) 2.25 (0.61–8.29)
1.1% (5) 2.25 (0.61–8.29)
2.5% (11) 1.54 (0.58–4.09)
4.0% (18) 0.63 (0.22–1.82)
2.5% (11) 0.51 (0.11–2.29)
1.8% (8) 0.70 (0.15–3.28)
11.8% (53) 1.81 (1.22–2.67)
1.8% (8) 2.11 (0.74–6.00)
0.4% (2) 2.82 (0.40–19.84)
1.3% (6) 1.88 (0.54–6.57)
10.3% (46) 1.78 (1.16–2.73)
5.8% (26) 2.38 (1.39–4.08)
5.8% (26) 1.19 (0.60–2.36)
sel CABG, and target vessel RPTCA; death, CVA, andMI are adjudicated by the independent clinicalVer
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Impact of Diabetes on 3-Year Outcome in the ARTS-II Trial December 9, 2008:1957–67RTS-I trial. As a consequence, we were unable to verify
he hypothesized increase in late stent thrombosis among
iabetic patients treated with DES as compared with BMS.
owever, it was reassuring to note the trend toward a lower
ate of death and a significantly lower rate of MI, as well as
-wave MI, in the ARTS-II population compared with the
RTS-I PCI population.
Several large-scale dedicated randomized controlled trials
ike the SYNTAX (Synergy Between Percutaneous Coro-
ary Intervention With Taxus and Cardiac Surgery) study
using the paclitaxel-eluting stent), the FREEDOM
Future REvascularization Evaluation in patients with
iabetes mellitus: Optimal management of Multivessel
isease) study (using the paclitaxel-eluting stent and
ES), and the CARDia (Coronary Artery Revasculariza-
ion in Diabetes) study (comparing SES with CABG for
iabetic patients) are ongoing to assess the relative safety
nd efficacy of PCI using DES and CABG (39,40).
owever, until the long-term outcome data from these
rials are revealed, the results from the present study are
nique in addressing the relative long-term safety and
fficacy of PCI using SES for both diabetic and nondiabetic
atients with multivessel coronary artery disease. The results
f the randomized FREEDOM and CARDia trials are
agerly awaited to confirm the findings of this analysis.
onclusions
t 3 years, PCI using SES for patients with multivessel
oronary artery disease seems to be safer and more efficacious as
ompared with PCI using BMS, irrespective of the diabetic
tatus of the patient. Although superior to PCI using BMS,
CI using SES remains inferior to CABG in reducing the
eed for repeat revascularizations. However, we observed a
lear trend toward a lower risk for death, CVA, and MI among
he ARTS-II study patients as compared with both arms of the
RTS-I trial. These findings suggest that PCI using SES
ould be a genuine alternative to CABG. The results of
edicated, large-scale, randomized trials are eagerly awaited to
alidate our findings.
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